Drugs.com - Clinical Trials

Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48

Merck Announces Positive Data from Phase 3 Trials that ...

Mar 13, 2025 0

RAHWAY, N.J.--(BUSINESS WIRE) March 12, 2025 -- Merck (NYSE: MRK), known as MSD...

ViiV Healthcare’s Investigational Broadly Neutralising Antibody - N6LS - Successfully Maintains Viral Suppression in Long-Acting Treatment of HIV

ViiV Healthcare’s Investigational Broadly Neutralising ...

Mar 13, 2025 0

London, 12 March 2025 – ViiV Healthcare, the global specialist HIV company major...

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

Arvinas and Pfizer Announce Positive Topline Results fr...

Mar 12, 2025 0

NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. ...

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart Announces Clinical Trial Initiation of Norovirus...

Mar 12, 2025 0

SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Na...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen Initiates Phase 3 Study of Felzartamab for the T...

Mar 11, 2025 0

CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) ...

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

First Clinical Data for Gilead’s Investigational Once-Y...

Mar 11, 2025 0

FOSTER CITY, Calif.--(BUSINESS WIRE) March 11, 2025 -- Gilead Sciences, Inc. (N...

Novo Nordisk Introduces NovoCare® Pharmacy, Lowering Cost of All Doses of FDA-Approved Wegovy® (semaglutide) to $499 per Month

Novo Nordisk Introduces NovoCare® Pharmacy, Lowering Co...

Mar 11, 2025 0

PLAINSBORO, N.J., March 5, 2025 /PRNewswire/ -- As part of its ongoing efforts t...

CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes in the REDEFINE 2 Trial

CagriSema Demonstrates Superior Weight Loss in Adults w...

Mar 11, 2025 0

Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline result...

Icotrokinra Meets Primary Endpoint of Clinical Response in Ulcerative Colitis Study and Shows Potential to Transform the Treatment Paradigm for Patients

Icotrokinra Meets Primary Endpoint of Clinical Response...

Mar 10, 2025 0

SPRING HOUSE, Pa. (March 10, 2025) – Johnson & Johnson (NYSE: JNJ) today announc...

Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

Tris Pharma Announces Positive Results from ALLEVIATE-2...

Mar 9, 2025 0

MONMOUTH JUNCTION, NJ, March 6, 2025 – Business Wire – Tris Pharma, Inc. (Tris),...

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical...

Mar 9, 2025 0

WALTHAM, Mass., March 8, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 ...

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Tr...

Mar 9, 2025 0

PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporatio...

Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite Study in Adults with Moderate to Severe Atopic Dermatitis

Amgen and Kyowa Kirin Provide Top-Line Results from Roc...

Mar 9, 2025 0

THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: A...

Icotrokinra Results Show Potential to Set a New Standard of Treatment in Plaque Psoriasis

Icotrokinra Results Show Potential to Set a New Standar...

Mar 9, 2025 0

SPRING HOUSE, Pa. (March 8, 2025) – Johnson & Johnson (NYSE: JNJ) today announce...

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Denali Therapeutics Announces Primary Analysis and Long...

Mar 7, 2025 0

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeuti...

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Plus Therapeutics Granted U.S. FDA Orphan Drug Designat...

Mar 6, 2025 0

HOUSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PST...

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advan...

Mar 5, 2025 0

CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (...

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301

Cingulate Reports Safety Results from Final Phase 3 Tri...

Mar 5, 2025 0

KANSAS CITY, Kan., March 04, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CI...

FDA Grants Orphan Drug Designation for Bexmarilimab in MDS

FDA Grants Orphan Drug Designation for Bexmarilimab in MDS

Mar 5, 2025 0

TURKU, Finland March 3, 2025 – Faron Pharmaceuticals Ltd. (AIM: FARN, First Nort...

Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies

Phase III Study Shows Xolair May Be More Effective With...

Mar 4, 2025 0

South San Francisco, CA -- March 2, 2025 -- Genentech, a member of the Roche Gro...

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Protagonist and Takeda Announce Positive Topline Result...

Mar 3, 2025 0

NEWARK, California, OSAKA, Japan and CAMBRIDGE, Massachusetts, March 3, 2025 – P...

Depemokimab Delivers Clinically Meaningful and Statistically Significant Improvements for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Depemokimab Delivers Clinically Meaningful and Statisti...

Mar 3, 2025 0

01 March 2025 -- GSK plc (LSE/NYSE: GSK) today announced full results from the p...

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

BioRestorative Receives FDA Fast Track Designation for ...

Mar 1, 2025 0

MELVILLE, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....

Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study

Emalex Biosciences’ Lead Candidate Meets Primary and Se...

Mar 1, 2025 0

CHICAGO—February 25, 2025—Emalex Biosciences announced positive topline data fro...

1
2
3
4
5

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.